Not checkedNot checked for notices yet.

Impact of GLP-1 receptor agonist-based therapies on cardiovascular and renal outcomes in diabetic and non-diabetic patients with CKD

Aliona Siniukovich, Christoforos K. Travlos, Sarah Freedman and 2 more

Diabetology & Metabolic Syndrome · 2025

doi:10.1186/s13098-025-01831-4 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

References33

17.
The PRISMA 2020 statement: an updated guideline for reporting systematic reviews · 2021
19.
Effect of the Glucagon-Like Peptide-1 Receptor Agonists Semaglutide and Liraglutide on Kidney Outcomes in Patients With Type 2 Diabetes: Pooled Analysis of SUSTAIN 6 and LEADER · 2022
31.
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial · 2024

30 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.